Jci_page_head_homepage_01 Jci_page_head_homepage_02
Giovanna Gallina, Luigi Dolcetti, Paolo Serafini, Carmela De Santo, Ilaria Marigo, Mario P. Colombo, Giuseppe Basso, Frank Brombacher, Ivan Borrello, Paola Zanovello, Silvio Bicciato, Vincenzo Bronte
Published in Volume 116, Issue 10
J Clin Invest. 2006; 116(10):2777–2790 doi:10.1172/JCI28828
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 9
Mechanisms of MSC-dependent suppression.

In the “triggering phase,” T lymphocytes activated by exposure to the antigen release IFN-γ that, possibly in conjunction with a not yet identified membrane signal, activates inflammatory monocyte precursors. Whereas in resting condition this would result in induction of classically activated macrophages, monocytes conditioned by tumors show a different program because of the expression of IL-4Rα and the ability to release both IL-13 and IFN-γ. The IFN-γ production, initially sustained by activated T lymphocytes, is subsequently amplified by the cytokine released from activated monocytes. IFN-γ allows the prolonged expression and signaling of IL-4Rα after engagement by IL-13 released via an autocrine circuit. During the “amplification phase,” the cytokines are thus able to maintain a prolonged activation of the enzymes NOS and ARG, which ultimately originate the immunosuppressive mediators acting on the CD8+ T cells. This model supports the view that a prolonged stimulation of MSCs is necessary to mediate a full inhibition of CD8+ T cells and explains why T cells can initially proliferate in the presence of spleen-derived MSCs. On the other hand, ARG and NOS are constitutively activated in tumor-infiltrating MSCs, which account for the prompt immunosuppression provided by these cells (Figure 1).